Schr'dinger Signs a Two-Year Research Collaboration with MD Anderson to Advance its WEE1 Program
Shots:
- MD Anderson to receive payments based on the development and commercialization of Schrödinger’s WEE1 inhibitor compounds. Schrödinger to provide research funding & will unite with researchers in MD Anderson's TRACTION platform to accelerate the development of new therapies
- Schrödinger will be responsible to develop- manufacture & commercialize the products & gets the rights to all novel intellectual property
- The focus of the collaboration is to accelerate & optimize the development of the WEE1 program through molecular biomarker-driven tumor type prioritization- patient stratification & validate biomarkers to predict response or resistance to a WEE1 inhibitor
| Ref: Businesswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com